The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

July 20, 2023

Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.

July 20, 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

July 20, 2023

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

July 20, 2023

Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.

July 20, 2023

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

July 20, 2023

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

July 19, 2023

Senthil Damodaran, MD, PhD, discusses the rationale for the phase 3 ELAINE-3 trial in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

July 17, 2023

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

July 17, 2023

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

July 13, 2023

Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.

July 13, 2023

Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.

July 13, 2023

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

July 13, 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.

July 13, 2023

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

July 13, 2023

Drs Tripathy and McArthur touch on the use of extended adjuvant therapy with neratinib and identify patients who might be suitable for this regimen, including those high-risk patients with residual disease after neoadjuvant therapy.

July 12, 2023

Treatment with ASP-1929 in combination with pembrolizumab led to responses and was well tolerated in patients with recurrent or metastatic head and neck squamous cell carcinoma.

July 12, 2023

Focused discussion on treatment guidelines and recommendations for fertility preservation while treating premenopausal patients with breast cancer.

July 12, 2023

A brief review of monitoring, response assessment, and treatment modification strategies used for patients with breast cancer undergoing OFS. .

July 10, 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 10, 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.